文献速递消化道肿瘤放疗胸部肿瘤放疗放疗物理与技术

靶向MerTK增强放疗后的适应性免疫应答

Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-04-18

研究在结直肠癌和胰腺癌小鼠模型中发现,MerTK缺失宿主接受放疗后肿瘤控制更佳,且依赖巨噬细胞和CD8 T细胞;华法林可模拟MerTK缺失表型,并与SABR治疗早期非小细胞肺癌患者无进展生存期改善相关。

要点

  • MerTK缺失增强放疗后肿瘤控制,依赖巨噬细胞和CD8 T细胞。
  • 华法林可模拟MerTK缺失表型,改善远隔效应。
  • 华法林使用与SABR治疗NSCLC患者更高无进展生存率相关。

核心结论

  • MerTK抑制SABR后的适应性免疫应答。
  • 华法林抑制MerTK信号并模拟其基因缺失,可能与SABR和免疫治疗联合有益。

研究设计与样本

  • 使用野生型和MerTK-/- BALB/c小鼠皮下接种CT26肿瘤并接受CT引导放疗。
  • 通过细胞清除研究验证巨噬细胞和CD8 T细胞的作用。
  • 在Panc02-SIY模型抗原系统中评估MerTK在放疗联合OX40激动抗体后免疫 priming 中的作用。
  • 在结直肠腺癌小鼠模型中展示华法林对野内和远隔效应的影响。
  • 多机构回顾性研究评估华法林与早期非小细胞肺癌SABR治疗患者无进展生存期的关联。

主要发现

  • MerTK-/-宿主放疗后肿瘤控制优于野生型小鼠,且呈巨噬细胞和CD8 T细胞依赖方式。
  • MerTK-/-小鼠在肿瘤定向放疗 alone 或联合OX40激动抗体后,外周血肿瘤抗原特异性CD8 T细胞计数增加。
  • 华法林治疗在单侧肿瘤放疗中模拟MerTK-/-表型,并改善放疗联合抗CTLA4的远隔效应。
  • 接受SABR的NSCLC患者中,华法林使用者无进展生存率高于非使用者。

临床怎么用

  • MerTK信号抑制可能作为增强放疗后适应性免疫应答的策略。
  • 华法林或可考虑与SABR和免疫治疗联合,但需进一步临床验证。

局限性

  • 研究主要基于小鼠模型,临床证据来自回顾性研究。
  • 华法林与SABR联合的获益需前瞻性临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of MerTK, a member of the Tyro3-Axl-MerTK family of receptor tyrosine kinase, in the immune response to radiation therapy (RT) is unclear. We investigated immune-mediated tumor control after RT in murine models of colorectal and pancreatic adenocarcinoma using MerTK wild-type and knock-out hosts and whether inhibition of MerTK signaling with warfarin could replicate MerTK knock-out phenotypes. METHODS AND MATERIALS: Wild-type and MerTK-/- BALB/c mice were grafted in the flanks with CT26 tumors and treated with computed tomography guided RT. The role of macrophages and CD8 T cells in the response to radiation were demonstrated with cell depletion studies. The role of MerTK in priming immune responses after RT alone and with agonist antibodies to the T cell costimulatory molecule OX40 was evaluated in a Panc02-SIY model antigen system. The effect of warfarin therapy on the in-field and abscopal response to RT was demonstrated in murine models of colorectal adenocarcinoma. The association between warfarin and progression-free survival for patients treated with SABR for early-stage non-small cell lung cancer was evaluated in a multi-institutional retrospective study. RESULTS: MerTK-/- hosts had better tumor control after RT compared with wild-type mice in a macrophage and CD8 T cell-dependent manner. MerTK-/- mice showed increased counts of tumor antigen-specific CD8 T cells in the peripheral blood after tumor-directed RT alone and in combination with agonist anti-OX40. Warfarin therapy phenocopied MerTK-/- for single-flank tumors treated with RT and improved abscopal responses for RT combined with anti-CTLA4. Patients on warfarin therapy when treated with SABR for non-small cell lung cancer had higher progression-free survival rates compared with non-warfarin users. CONCLUSIONS: MerTK inhibits adaptive immune responses after SABR. Because warfarin inhibits MerTK signaling and phenocopies genetic deletion of MerTK in mice, warfarin therapy may have beneficial effects in combination with SABR and immune therapy in patients with cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tormoen GW, Blair TC, Bambina S, et al. Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32311417. doi:10.1016/j.ijrobp.2020.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。